Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target
HIPEC
No preference
No preference

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT03772028IIINewly diagnosed stage III ovarian cancer eligible for primary cytoreductive surgeryPhase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal ChemotherapyCA, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
HIPECHyperthermic Intraperitoneal ChemotherapyNCCN Guidelines for Ovarian Cancer
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
NCT05659381IIINewly diagnosed stage III/IV high grade serous or endometrioid ovarian cancer (neo-adjuvant)GOG-3068: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Cisplatin Versus no HIPEC at the Time of Optimal Interval Cytoreductive Surgery Followed by Niraparib Maintenance in Patients With Newly Diagnosed Stage III and IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (Heated Ovarian Treatment Trial)CA, KY, NJ, OH, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
HIPECHyperthermic Intraperitoneal ChemotherapyNCCN Guidelines for Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04847063INewly diagnosed or recurrent ovarian cancer with peritoneal diseaseIndividualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma HistologiesMDView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
HIPECHyperthermic Intraperitoneal ChemotherapyNCCN Guidelines for Ovarian Cancer
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
Doxorubicin14-Hydroxydaunomycin, Hydroxyl-DaunorubicinTopoisomerase II inhibitorApproved in Other Cancers
OxaliplatinOHP, Eloxatine, Dacplat, Dacotin, EloxatinDNA damaging agent
SurgeryClinical Trials
NCT06216561IAdvanced solid tumors with periotoneal metastases that are candidates for cytoreductive surgery - intraperitoneal infusionA Phase I Trial of Intraperitoneal LSTA1 in Patients Undergoing Cytoreductive Surgery and HIPEC for Peritoneal Surface MalignancyCAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
HIPECHyperthermic Intraperitoneal ChemotherapyNCCN Guidelines for Ovarian Cancer
LSTA1internalized-arginylglycylaspartic acid cyclic peptide, CEND1Increases vascular permeability of tumor blood vessels and promotes tumor penetrationClinical Trials

If you have any questions or would like help with your search, please call us at: 858-264-6889 or email us at patientsupport@clearityfoundation.org.